SG11201900138TA - Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof - Google Patents

Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Info

Publication number
SG11201900138TA
SG11201900138TA SG11201900138TA SG11201900138TA SG11201900138TA SG 11201900138T A SG11201900138T A SG 11201900138TA SG 11201900138T A SG11201900138T A SG 11201900138TA SG 11201900138T A SG11201900138T A SG 11201900138TA SG 11201900138T A SG11201900138T A SG 11201900138TA
Authority
SG
Singapore
Prior art keywords
international
rule
ligand
pct
applicant
Prior art date
Application number
SG11201900138TA
Inventor
Brian Rabinovich
Natalia Martin-Orozco
Laszlo Radvanyi
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of SG11201900138TA publication Critical patent/SG11201900138TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 011101011M 01 110 1001110111H 1101 MO IMEMOVOIMIE Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/009894 Al 11 January 2018 (11.01.2018) W I PO I PCT (51) International Patent Classification: (74) Agent: MACDOUGALL, Christina, A. et al.; Morgan, CO7K 16/28 (2006.01) Lewis & Bockius LLP, One Market, Spear Tower, San Fran- (21) International Application Number: cisco, CA 94105 (US). PCT/US2017/041241 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 07 July 2017 (07.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/359,612 07 July 2016 (07.07.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: IOVANCE BIOTHERAPEUTICS, INC. TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, — (72) Inventors: RABINOVICH, Brian; 98 Hill Coutry Drive, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Stouffville, ON L4A 7X5 (CA). MARTIN-OROZCO, Na- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, talia; 98 Canterbury Hill Road, Action, MA 01720 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, RADVANYI, Laszlo; 98 Canterbury Hill Road, Action, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MA 01720 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = Title: PROGRAMMED DEATH 1 LIGAND 1 (PD-L1) BINDING PROTEINS AND METHODS OF USE THEREOF — (54) = Figure 3 = 2 A 19E19-scFV-Fr 3 1 = = = — , = = = EC50 t -= 0,4039 - _ = = Maxibody Concentration (tog MA ,—, 7r C:7 GC (57) : The present disclosure provides proteins, such as antibodies, that include an antigen binding portion that specifically 01 binds to Programmed Death 1 Ligand 1 (PD-L1). Also provided are nucleic acids encoding the proteins, and cells (e.g., genetically modified cytotoxic lymphocytes) that include such nucleic acids. In some embodiments, a subject method includes reducing the inter- = - --- GC action between PD-L1 on a first-cell and PD-1 on a second cell. In some cases, the contacting is in vivo. For example, the methods and compositions provided can be used in the treatment of viral infection and cancer, such as the treatment of solid tumors via ACT or via C::::) administration of a subject protein that specifically binds to PD-L1. ei C [Continued on next page] WO 2018/009894 Al MIDEDIMOMOIDEIREEMOOVIRIMOIMOHIMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201900138TA 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof SG11201900138TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359612P 2016-07-07 2016-07-07
PCT/US2017/041241 WO2018009894A1 (en) 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201900138TA true SG11201900138TA (en) 2019-02-27

Family

ID=59366537

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900138TA SG11201900138TA (en) 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Country Status (15)

Country Link
US (2) US11141434B2 (en)
EP (1) EP3481867A1 (en)
JP (1) JP7093771B2 (en)
KR (1) KR102630017B1 (en)
CN (1) CN109843921B (en)
AU (1) AU2017292889A1 (en)
BR (1) BR112019000185A2 (en)
CA (1) CA3030156A1 (en)
EA (1) EA201990230A1 (en)
IL (1) IL264104B1 (en)
MA (1) MA45595A (en)
MX (1) MX2019000149A (en)
NZ (1) NZ750005A (en)
SG (1) SG11201900138TA (en)
WO (1) WO2018009894A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
WO2015085162A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102128856B1 (en) 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 system for ablating undesirable soft tissue in a living subject using radio frequency electrical membrane breakdown
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
KR20180108655A (en) * 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 Immunological treatment of cancer
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
GB2605540B (en) * 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
CA3085784A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer driver and controller
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP2023507432A (en) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド Devices and methods for isolating tumor-infiltrating lymphocytes and uses thereof
WO2024040138A1 (en) 2022-08-17 2024-02-22 Purdue Research Foundation Universal natural killer cells derived from human pluripotent stem cells and method of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
JP2001500015A (en) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Method for producing inducible recombinant adeno-associated virus using T7 polymerase
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
EP1545204B1 (en) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CN103173354B (en) 2003-10-08 2017-07-14 威尔森沃尔夫制造公司 The method and device of cell culture is carried out using poromeric material
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
CN101104640A (en) * 2006-07-10 2008-01-16 苏州大学 Preparation for anti human PD-L1 monoclonal antibody and application thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8556882B2 (en) 2009-04-30 2013-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
SG181559A1 (en) 2009-12-08 2012-07-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
RS61854B1 (en) 2010-11-12 2021-06-30 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
HUE031348T2 (en) 2011-10-21 2017-07-28 Cell Medica Ltd Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
IL307674A (en) 2012-05-18 2023-12-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
AU2013274416B2 (en) 2012-06-11 2019-07-04 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
CN105163745B (en) 2013-03-01 2020-06-12 美国卫生和人力服务部 Method for generating enriched populations of tumor-reactive T cells from peripheral blood
CN103242448B (en) * 2013-05-27 2015-01-14 郑州大学 Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
US9840692B2 (en) 2013-06-24 2017-12-12 Wilson Wolf Manufacturing Closed system device and methods for gas permeable cell culture process
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
MX2016012176A (en) 2014-03-20 2017-04-13 H Lee Moffitt Cancer Ct & Res Tumor-infiltrating lymphocytes for adoptive cell therapy.
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
MY180750A (en) 2014-06-11 2020-12-08 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
DK3193931T3 (en) * 2014-09-16 2020-10-19 Innate Pharma NEUTRALIZATION OF INHIBITORY ROADS IN LYMPHOCYTE
JP6686008B2 (en) 2014-10-02 2020-04-22 アメリカ合衆国 Method for isolating T cell receptor having antigen specificity for cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
EP3233900A2 (en) * 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
MX2019004707A (en) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Restimulation of cryopreserved tumor infiltrating lymphocytes.
CA3049163A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
CN110832070A (en) 2017-05-10 2020-02-21 艾欧凡斯生物治疗公司 Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

Also Published As

Publication number Publication date
EA201990230A1 (en) 2019-07-31
CN109843921A (en) 2019-06-04
BR112019000185A2 (en) 2019-04-16
MX2019000149A (en) 2019-09-23
IL264104A (en) 2019-01-31
US11141434B2 (en) 2021-10-12
KR102630017B1 (en) 2024-01-25
JP7093771B2 (en) 2022-06-30
KR20190038825A (en) 2019-04-09
IL264104B1 (en) 2024-04-01
JP2019525771A (en) 2019-09-12
WO2018009894A1 (en) 2018-01-11
US20190298770A1 (en) 2019-10-03
AU2017292889A1 (en) 2019-02-14
CA3030156A1 (en) 2018-01-11
NZ750005A (en) 2023-06-30
MA45595A (en) 2019-05-15
CN109843921B (en) 2023-05-26
US20220025052A1 (en) 2022-01-27
EP3481867A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201908540PA (en) Stable antibody formulation
SG11201908131RA (en) Benzazepine compounds, conjugates, and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807187XA (en) Binding members to pd-l1
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811432WA (en) Rna for cancer therapy
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201909011PA (en) Niraparib compositions
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof